A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma-Reference-Cited by-同舟云学术

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma

Published:2013-12 Issue:12 Volume:24 Page:3076-3081
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Evens A.M.,Carson K.R.,Kolesar J.,Nabhan C.,Helenowski I.,Islam N.,Jovanovic B.,Barr P.M.,Caimi P.F.,Gregory S.A.,Gordon L.I.

Funder

AME

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/12/3076/16702496/mdt414.pdf

Reference19 articles.

1. Burkitt's and Burkitt-like lymphoma;Evens;Curr Treat Options Oncol,2002

2. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases;Costa;Blood,2013

3. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen;Magrath;J Clin Oncol,1996

4. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study;Mead;Ann Oncol,2002

5. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial);Mead;Blood,2008

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis and Treatment of Burkitt Lymphoma in Adults: Clinical Practice Guidelines from ERN-EuroBloodNet "Recommendations Carried Out within the Framework of European Reference Network on Rare Haematological Diseases (ERN-EuroBloodNet)-Project ID No 10108571. ERN-EuroBloodNet is Partly Co-Funded by the European Union within the Framework of the Fourth EU Health Programme";2024

2. Burkitt's Lymphoma;Comprehensive Hematology and Stem Cell Research;2024

3. Andrographolide inhibits Burkitt’s lymphoma by binding JUN and CASP3 proteins;Cancer Chemotherapy and Pharmacology;2023-12-26

4. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial;The Lancet Haematology;2023-12

5. China Anti-Cancer Association (CACA) guidelines for holistic integrative management of lymphoma (version 2022);Holistic Integrative Oncology;2023-11-27